NCT04509141 Acupuncture as Migraine Prophylaxis in Reducing Frequency, Duration and Intensity of Migraine With Minimum Acupoint, Seen up to Eight Weeks From Baseline Status COMPLETED Phase NA
NCT04503083 BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies Status COMPLETED Phase N/A
NCT04492020 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants Status COMPLETED Phase PHASE3
NCT04473976 Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects Status COMPLETED Phase N/A
NCT04464707 A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age Status COMPLETED Phase PHASE3
NCT04463875 Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis Status COMPLETED Phase N/A
NCT04461795 Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden Status COMPLETED Phase PHASE4
NCT04458857 A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age Status COMPLETED Phase PHASE3
NCT04452929 The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients Status UNKNOWN Phase NA
NCT04418765 A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments Status COMPLETED Phase PHASE3
NCT04413110 PSG and Neuroendocrine Hormones in Subjective Cognitive Impaired Patients With Transformed Migraine Status COMPLETED Phase N/A
NCT04406649 A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Status COMPLETED Phase PHASE3
NCT04401137 The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects Status COMPLETED Phase PHASE1
NCT04396574 A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine Status TERMINATED Phase PHASE3
NCT04396236 A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine Status TERMINATED Phase PHASE3
NCT04384367 Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine Status COMPLETED Phase PHASE3